Overview
LDS’s proprietary platform technology enables the embedment of large loads of active molecules, including poorly permeable, soluble or non-soluble active molecules solubilized on the interface of liquid nano-domains interfaces. The nano-structures are used in the pharmaceutical, nutraceutical, and cosmeceutical industries. The “flexible” nano-structures consist of lipid-based ingredients loaded with “membrane recognition”, “permeation agents”, and the active molecules on their interface, or core. The unique technology consists of homogeneous nano-structures with a maximum size of 50nm, forming transparent fluids. The nano-structures are non-expensive to manufacture (simple scale-up), requiring almost no energy input or unique equipment, and can be made at any temperature. The nano-domains are physically extremely stable, with a long shelf-life, and can be stored either as liquids or in powder form to be further used as creams, tablets, sprays, films, gels, and more.
Unlike solid nano-particles that are not recommended by regulatory authorities (including the FDA and EMA) because of their involvement in cell apoptosis, LDS’s nano-domains are liquids and are considered safe and non-toxic.
We use the most sophisticated and advanced equipment
We have access to state-of-the-art analytical tools in our own laboratories or in the Nano-Center at the Hebrew University, which allows us to characterize and to understand the nano-domain structures and properties profoundly, both in the development stages and after production.
Unique structure that enhances delivery
The core technology at LDS is derived from new molecular engineering models that allow the formation of new types of modified nano-domains. The domains are “coronated” in their interface with membrane recognition molecules and permeation agents facilitating the active molecule’s efficient transport.
The structures enable intimate contact with the target tissue surfaces, facilitating the diffusion of the active molecule across the membrane. Furthermore, the structures include components that allow the delivery of the active molecule to the surfaces or the membrane’s interface without any intermediary.
Controlled release at the required rate
LDS carefully selects the proper ingredients to allow each nano-domain to solubilize a specific active molecule at a required loading capacity. The nature of the active molecule and its embedding on the interface of the nano-domains (and not in their core) can be manipulated to achieve controlled release.
We customize the active molecule release using few proprietary nano-structures that work together to optimize the active molecule solubility and deliverability and the order of the structure.
Chaotropic guest molecules
disordering the structure
Cosmotropic guest molecules increasing the order
How does it work?
The tailor-made ‘oily’ nano-domains are designed and prepared by loading the active molecules at the interface or core of the structures. The domains are coronated with several excipients facilitating the permeation of the active molecules across surfaces, or membranes (‘permeating agents’). Only once the nano-domains migrate to the interface and recognize the delivery site will the structure adhere to the surface and allow the active molecule to be released by diffusion.
The delivery is processed in four main steps:
Migration of the nano-domains to the membrane
The nano-domains recognize the specific membrane surface onto which they will adhere.
The nano-domains adhere to the membrane
The nano-domains adheres to the membrane and the active molecule is released by membrane undulation.
Active molecules permeate the membrane
The nano-domains’ intimate contact with the membrane allows passive diffusion of the active molecules.
The nano-domains depart from the membrane
The empty vehicles depart from the adsorbing site and are discharged from the body.
Publications
Tehila Mishraki-Berkowitz Guy Cohen Abraham Aserin, N. Garti. Colloids Surfaces B, Biointerfaces 2018, 12;161: 670-676.
R.E. Hoffman, E. Darmon, A. Aserin, N. Garti, Part 1- Proof of concept. Journal of Colloid and Interface Science, 2016, 463, 349-357.
T. Mishraki-Berkowitz, P. Ben Ishai, A. Aserin, Yu. Feldman, N. Garti. Physical Chemistry Chemical Physics,2015, 17(14), 9499-9508.
M. Cohen-Avrahami, A. I. Shames2, M. F. Ottaviani3, A. Aserin, N. Garti, Colloids and Surfaces B. Biointerfaces, 2014, 122, 231-240.
V.L. Kolev, A.N. Ivanova, G.K. Madjarova, A. Aserin, N. Garti, Journal of Physical Chemistry B, 2014, 118(20), 5459-5470.
L. Bitan-Cherbakovsky, A. Aserin, N. Garti, Colloids and Surfaces, B: Biointerfaces ,2013, 112, 87-95.
T. Mishraki, P. Ben Ishai, D. Babukh, A. Aserin, Y. Feldman, N. Garti, Journal of Colloid and Interface Science; 396, 2013178-186.
M. Cohen-Avrahami, D. Libster, A. Aserin, N. Garti, Journal of Controlled Release,2012, 159(3), 419–428.
I. Amar-Yuli, J. Adamcik, S. Blau, A. Aserin, N. Garti, R. Mezzenga, Soft Matter ,2011, 7(18), 8162-8168.
J. Gurfinkel, A. Aserin, N. Garti, Colloids and Surfaces A: Physicochemical and Engineering Aspects ,2011, 392(1), 322-328. D. Libster, A. Aserin, N. Garti. Interactions of biomacromolecules with reverse hexagonal liquid crystals: Drug delivery and crystallization applications. Journal of Colloid and Interface Science ,2011, 356(2), 375-386.4.
L. Bitan-Cherbakovsky, D. Libster, A. Aserin, N. Garti, Journal of Physical Chemistry B, 2011, 115(42), 11984-11992.
R. Efrat, Z. Abramov, A. Aserin, N. Garti, Journal of Physical Chemistry B ,2010, 114(33), 10709-10716.
L. Bitan-Cherbakovsky, I. Yuli-Amar, A. Aserin, N. Garti, Langmuir,2010, 26(5), 3648-3653.
T. Mishraki, D. Libster, A. Aserin, N. Garti, Colloids Surf. B 2010, 75(2), 391-397.
Patents
Enclosed is a list of the approved and the filed patents of LDS new delivery technology. The patents list is providing a quick glance and an introduction of LDS patents family.
Hexagonal systems for use in solubilizing, protecting and delivery of bio-macromolecule and/or active compounds.
Patents granted.
Mediums and methods for selective extraction of active compounds from plant material (including selective cannabinoids extraction).
Pending patent applications.
Solubilization in high loads of cannabinoids for fast and efficient delivery for oral applications
Pending patent applications.
Various novel nano-domains formulations for various administration routes of active compounds, including injectables, oral, topical formulations, etc.
Pending patent applications and granted patents.
